EN DE
Check 35,000+ stocks against 26 valuation models and 37 quality factors
Data-driven stock valuation

Novolog Pharm-Up 1966 Ltd (NVLG) fair value: what the stock is really worth

As of Sep 24, 2026: fair value of Novolog Pharm-Up 1966 Ltd ILS 0.23, price ILS 0.84, upside -72.6%, quality 43 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.

  1. Fair value above price? No
  2. Good quality? No
  3. Add to watchlist

Healthcare · Il · ISIN IL0011401515

NP Thin data Sep 24, 2026

Novolog Pharm-Up 1966 Ltd

NVLG · TA

Weakest SetupStrongly overvalued and low quality.

!Fair value 0.2300 ILA · Strongly overvalued (−73%)
!Quality 43/100
!Expensive Growth (revenue 5y +9.8 %/yr)
!Thin margins · 0.2% net margin (TTM)
!Low debt · negative free cash flow
·4.64% dividend yield
!Trails peers (4/12)
!Narrow moat 19/100
!Insider activity 40/100
!Evidence only low, so the estimate is less certain
!Weak on past: 4 out of 100
Watch Novolog Pharm-Up 1966 Ltd for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card. Watch for free Pro now: $1 first month

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

3.25 ILA 0.6680 ILA Fair Value 0.2300 ILA Jun 2021 Sep 2026

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 24, 2026.

How to read this chart

60‑month range 0.6680 ILA – 3.25 ILA · fair‑value band 0.1300 ILA – 0.2400 ILA · the 0.8400 ILA price screens above the 0.2300 ILA fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). 1 fiscal year is left out: there the valuation rested on only a fraction of the usual models. Dashed = 300-day average. As of Sep 24, 2026.

Follow Novolog Pharm-Up 1966 in your weekly email

Every Wednesday you see whether Novolog Pharm-Up 1966 is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Novolog (Pharm-Up 1966) Ltd provides healthcare services in Israel. The company operates through three divisions: Logistics, Healthcare Services, and Digital.

Show more

Novolog (Pharm-Up 1966) Ltd provides healthcare services in Israel. The company operates through three divisions: Logistics, Healthcare Services, and Digital. The Logistics division engages in the import and distribution of pharmaceuticals and medical products; logistics of clinical trials and related services; provision of pharmaceutical services to customers; and sterilization and validation processes of consumable medical equipment. The Healthcare Services division provides personalized medicine, medical and diagnostic laboratory, and other medical services to patients, health organizations, insurance companies, multinational companies, and government bodies. The Digital division identifies and develops technological tools for health services; deals with making medical information accessible to the public through medical websites; promotes digital presence for clinics, doctors therapists, and medical bodies; provides services and management tools; and operates and markets digital platforms for doctors and clinics. In addition, the company provides appointment scheduling, calendar management, and telemedicine meeting management. Novolog (Pharm-Up 1966) Ltd was incorporated in 1966 and is headquartered in Modi'in-Maccabim-Re'ut, Israel.

Stock analysis

Novolog Pharm-Up 1966 Ltd (NVLG) currently trades at 0.8400 ILA, while our model-based Fair Value estimate is 0.2300 ILA, implying the stock looks roughly 265.2% overvalued today.

Show more

Valuation

Bull case: the Asset-Based group reads highest at a median of 0.4700 ILA per share, and 4 of the 17 models we run sit above the 0.8400 ILA price.

Bear case: the Earnings-Based group reads lowest at 0.0800 ILA, and 13 of the 17 models stay below the price. Evidence for this calculation is low.

Scenario range: 0.1300 ILA (bear) to 0.2400 ILA (bull), the price of 0.8400 ILA sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 43/100 (below-average quality), in the Healthcare sector.

Expensive Growth: The company is growing, but growth may require heavy reinvestment or weak cash conversion.

Novolog Pharm-Up 1966 Ltd reported revenue of 1.8B ILS in FY2025 versus 1.3B ILS in FY2021, a compound +9.5%/yr. Reported net income was 4.1M ILS in FY2025, compounding −44.2%/yr from FY2021.

Key figures

Market cap 429M ILA · P/E ratio 84.0 · P/S ratio 0.19 · EPS (TTM) 0.0100 ILA · Dividend yield 4.6% · Net margin 0.2% · Return on equity 0.9% · Return on assets (EBIT) 1.9%.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 32 out of 100 (low confidence).

What moves the price

The share trades about 38% below its 52-week high and 26% above its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at 35% fair-value upside, at −73%, NVLG screens richer than that median.

Fair Value models

Bear 0.1300 ILA Fair Value 0.2300 ILA Bull 0.2400 ILA
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Highest evidence
Owner Earnings 1.61 ILA 2.32 ILA 3.31 ILA 77
Residual Income 0.4300 ILA 0.4000 ILA 0.2500 ILA 76
EPV 0.5700 ILA 0.6100 ILA 0.6400 ILA 74
All 17 models by family
DCF Models
Owner Earnings 1.61 ILA 2.32 ILA 3.31 ILA 77
Earnings-Based
Graham-Dodd 0.0500 ILA 0.2300 ILA 0.3100 ILA 64
Lynch FV 0.0600 ILA 0.0800 ILA 0.1100 ILA 61
PEG = 1.0 0.0600 ILA 0.0800 ILA 0.1100 ILA 57
EPV 0.5700 ILA 0.6100 ILA 0.6400 ILA 74
Dividend Discount
Gordon GGM 0.2700 ILA 0.4600 ILA 0.5900 ILA 68
DDM Multi-Stage 0.2700 ILA 0.4300 ILA 0.4900 ILA 67
Multiples
P/E Multiple 0.1300 ILA 0.1800 ILA 0.2200 ILA 63
P/S Multiple 0.1000 ILA 0.1400 ILA 0.1700 ILA 58
P/B Multiple 0.1000 ILA 0.1400 ILA 0.1700 ILA 55
EV/EBIT 0.9000 ILA 1.12 ILA 1.34 ILA 66
EV/EBITDA 2.31 ILA 3.00 ILA 3.69 ILA 67
EV/Revenue 0.7100 ILA 0.9100 ILA 1.11 ILA 54
Asset-Based
NCAV (Graham) 0.3500 ILA 0.4700 ILA 0.7000 ILA 54
Economic Profit
Residual Income 0.4300 ILA 0.4000 ILA 0.2500 ILA 76
ROIC Compounder 0.5700 ILA 0.6100 ILA 0.6400 ILA 72
Growth Earnings
Growth-Adj P/E 0.1000 ILA 0.1400 ILA 0.1900 ILA 67

Open the full fair value analysis →

Notify me when NVLG reaches fair value

Put NVLG on your watchlist. We get in touch as soon as price and fair value meet or the trend turns.

Set up alert →

Quality Score breakdown

Overall quality 43/100

Of which business quality 41 · Market factors (momentum, volatility) 35

Profitability 25
Margins and returns on capital today
Quality Growth 40
Are margins and returns improving?
Cashflow 11
Earnings quality: real cash, not paper profit
Fin. Strength 29
Balance sheet, leverage, solvency risk
Investment 100
Disciplined investing over empire-building
Low Volatility 77
Calm price path (market factor)
Momentum 21
Price trend over the last 3–12 months (market factor)
52W Momentum 13
Distance to the 52-week high (market factor)
Net Issuance 83
Share count: buybacks or dilution?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 42/100
The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Revenue growth 1 year
−10.7%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+6.2%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+9.8%
Start year 2020 (pandemic). Over 10 years: +10.2% a year
Revenue growth 12 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+10.5%
What shareholders gained per year (last 5 years) ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate.
−32.6%
Earnings growth per share plus dividend.
Earnings per share, growth per year−37.2%
Dividend (yield on the price)4.6%
Pace: 5 vs 10 years ⓘTwo data points, not a trend model: earnings growth per share over the last 5 fiscal years against the last 10. Labelled "steady" when both rates are within 3 percentage points of each other, otherwise picking up or flattening. Shown only when ten years of history exist.−37% vs −20%, slowing
Profit margin 2020 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.5% → 2%
Start year 2020 (pandemic)

NVLG screens 265% overvalued. Compare with McKesson Corporation →

Compare Novolog Pharm-Up 1966 Ltd with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Medical Distribution · 83 stocks

Beats the industry median on 3/11 measures
Overall it trails its industry peers.
Valuation
Quality Score 43 · Bottom 25%
Fair Value upside −72% · Bottom 25%
Profitability
Return on equity (TTM) 1% · Below median
Return on assets 1% · Below median
Net margin (TTM) 0% · Below median
Operating margin (TTM) 1% · Bottom 25%
Growth and dividend
Revenue growth 0% · Below median
Dividend yield (TTM) 4.6% · Top 25%

Valuation Multiplesvs Medical Distribution median · lower = cheaper

P/E (TTM) 84.0× · Priciest 25%
P/B 0.38× · Cheapest 25%
P/S (TTM) 0.08× · Cheapest 25%

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)0 · sector 42
FUTURE (revenue growth)0 · sector 17
PAST (return on equity)4 · sector 27
HEALTH (low debt)100 · sector 96
DIVIDEND (yield)93 · sector 59

VALUE 0: the price sits above our fair-value range.

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Medical Distribution stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value
McKesson Corporation MCK $891.23 $819.31 −8%
Cencora, Inc COR $314.43 $211.07 −33%
Cardinal Health, Inc CAH $222.04 $141.77 −36%
Henry Schein, Inc HSIC $87.43 $76.86 −12%
Shanghai Pharmaceuticals Holding 601607 ¥16.06 ¥42.67 +166%
Sinopharm Group 1099 HK$15.06 HK$58.89 +291%
Galenica AG GALE CHF 83.45 CHF 61.79 −26%
Guangzhou Baiyunshan Pharmaceutical Holdings 600332 ¥19.67 ¥26.64 +35%
Jointown Pharmaceutical Group 600998 ¥4.89 ¥9.84 +101%
China National Medicines Corporation 600511 ¥26.11 ¥58.47 +124%

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names ⭐ Top Rated 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Calculator with industry benchmark Peter Lynch Fair Value Formula &…Calculator with industry benchmark
Run the numbers yourself: free valuation calculators
DCF CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorFama-French ModelIntrinsic Value
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Novolog Pharm-Up 1966 Ltd · Fair Value
0.2300 ILA −265%Fair Value
Calculator →

Cite: Fair Value Calculator (2026). "Novolog Pharm-Up 1966 Ltd Fair Value". https://www.fairvalue-calculator.com/stock/NVLG

Frequently asked questions

Is Novolog Pharm-Up 1966 Ltd (NVLG) overvalued or undervalued?
As of Sep 24, 2026, our model estimates a fair value of 0.2300 ILA versus a price of 0.8400 ILA, about −73% upside (overvalued).
What is the fair value of NVLG?
Our model-based fair value for Novolog Pharm-Up 1966 Ltd is 0.2300 ILA (as of Sep 24, 2026), built from audited fundamentals. The current price: 0.8400 ILA.
What is the quality score of NVLG?
Novolog Pharm-Up 1966 Ltd has a Quality Score of 43/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Novolog Pharm-Up 1966 Ltd (NVLG)?
Our model-based price target is the fair value of 0.2300 ILA (as of Sep 24, 2026) from 17 valuation models. Cautious scenario 0.1300 ILA, optimistic scenario 0.2400 ILA. It is a calculation from audited fundamentals, not an analyst target.
What is the Novolog Pharm-Up 1966 Ltd stock forecast for 2026?
Our models put fair value at 0.2300 ILA, about −73% upside versus a price of 0.8400 ILA (overvalued). Cautious scenario 0.1300 ILA, optimistic scenario 0.2400 ILA. The calculation is refreshed regularly with new filings.
What is the revenue of Novolog Pharm-Up 1966 Ltd (NVLG)?
Novolog Pharm-Up 1966 Ltd reported trailing-twelve-month revenue of about 1.8B ILS (latest available figure, as of Sep 24, 2026).
Does Novolog Pharm-Up 1966 Ltd pay a dividend?
Novolog Pharm-Up 1966 Ltd currently shows a dividend yield of about 4.64% relative to its recent price (as of Sep 24, 2026).
What is the intrinsic value of Novolog Pharm-Up 1966 Ltd (NVLG)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Novolog Pharm-Up 1966 Ltd it is 0.2300 ILA per share (as of Sep 24, 2026), against a price of 0.8400 ILA. It is the blended result of 17 valuation models (cash flow, earnings, asset, dividend).
Is Novolog Pharm-Up 1966 Ltd stock overvalued or undervalued in 2026?
As of Sep 24, 2026, NVLG trades above its calculated fair value: price 0.8400 ILA, fair value 0.2300 ILA, a gap of about −73% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of NVLG?
No. The price is what the market pays today (0.8400 ILA); the fair value is what the company's own numbers justify (0.2300 ILA). For Novolog Pharm-Up 1966 Ltd the two are 0.6100 ILA per share apart. That gap is exactly why we show both numbers side by side.
How much is Novolog Pharm-Up 1966 Ltd worth?
The market values Novolog Pharm-Up 1966 Ltd at about 429M ILA (market capitalisation, as of Sep 24, 2026). Per share that is 0.8400 ILA; our models calculate a fair value of 0.2300 ILA per share.
What do the bullish and bearish scenarios say about NVLG?
Our models span a range for Novolog Pharm-Up 1966 Ltd: cautious scenario 0.1300 ILA, base 0.2300 ILA, optimistic 0.2400 ILA per share (as of Sep 24, 2026, price 0.8400 ILA). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of NVLG?
Novolog Pharm-Up 1966 Ltd trades at a price-to-earnings ratio of 84.0 (as of Sep 24, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of 0.2300 ILA is built from several models across several years. Other multiples: P/B 0.4, P/S 0.1.
How solid is the balance sheet of Novolog Pharm-Up 1966 Ltd (NVLG)?
Balance-sheet figures for Novolog Pharm-Up 1966 Ltd (as of Sep 24, 2026): return on equity 0.9%. They feed the Quality Score of 43/100, which measures business quality independently of the share price.
How far is NVLG from its 52-week high?
Novolog Pharm-Up 1966 Ltd trades at 0.8400 ILA, about 38% below its 52-week high of 1.36 ILA and 26% above the low of 0.6680 ILA (as of Sep 24, 2026). Distance from the high says nothing about value: that is what the fair value of 0.2300 ILA is for.
Which stocks are comparable to Novolog Pharm-Up 1966 Ltd?
From the same area (Healthcare) we also value McKesson Corporation, Cencora, Inc, Cardinal Health, Inc, Henry Schein, Inc, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Novolog Pharm-Up 1966 Ltd stock attractive at the current price?
The data as of Sep 24, 2026: price 0.8400 ILA, calculated fair value 0.2300 ILA (−73%), Quality Score 43/100, from 17 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of NVLG calculated?
We run Novolog Pharm-Up 1966 Ltd through 17 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of 0.2300 ILA, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.2 % above its aggregate fair value. Novolog Pharm-Up 1966 Ltd itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Novolog Pharm-Up 1966 Ltd (NVLG)?
The closing price on Sep 24, 2026 was 0.8400 ILA. Our model-based fair value is 0.2300 ILA, about −73% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Novolog Pharm-Up 1966 Ltd right now?
The price sits above even our optimistic bull case (0.2400 ILA). The favourable scenario is already priced in. Weak quality (43/100) and above fair value at the same time, the margin of safety is missing on both counts. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. A fairly wide model range (0.1300 ILA to 0.2400 ILA) leaves room in how you read the outcome.
Where does the earnings growth of Novolog Pharm-Up 1966 Ltd (NVLG) come from?
Earnings per share at Novolog Pharm-Up 1966 Ltd grew −5.6 % a year from 2014 to 2025. Broken into its drivers: revenue per share +7.1 %, EBIT margin −8.6 %, tax rate −0.6 %, residual (interest, one-offs) −3.0 %. The four rates multiply to the earnings growth rate, they do not add up. Start and end are three-year averages so a single exceptional year does not distort the result.

Key figures of Novolog Pharm-Up 1966 Ltd

How large is the market capitalisation of Novolog Pharm-Up 1966 Ltd (NVLG)?
The market capitalisation of Novolog Pharm-Up 1966 Ltd is 429M ILA. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Novolog Pharm-Up 1966 Ltd (NVLG)?
The price-to-sales ratio of Novolog Pharm-Up 1966 Ltd is 0.19 (P/E × margin). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Novolog Pharm-Up 1966 Ltd (NVLG)?
Earnings per share at Novolog Pharm-Up 1966 Ltd are 0.0100 ILA (price ÷ EPS = P/E 84.0). Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of Novolog Pharm-Up 1966 Ltd (NVLG)?
The dividend yield of Novolog Pharm-Up 1966 Ltd is 4.6%. Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of Novolog Pharm-Up 1966 Ltd (NVLG)?
The net margin of Novolog Pharm-Up 1966 Ltd is 0.2% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Novolog Pharm-Up 1966 Ltd (NVLG)?
The return on equity (ROE) of Novolog Pharm-Up 1966 Ltd is 0.9% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Novolog Pharm-Up 1966 Ltd (NVLG)?
On an EBIT basis the return on assets of Novolog Pharm-Up 1966 Ltd is 1.9% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Novolog Pharm-Up 1966 Ltd (NVLG)?
The operating margin of Novolog Pharm-Up 1966 Ltd is 1.0% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Novolog Pharm-Up 1966 Ltd (NVLG)?
Revenue at Novolog Pharm-Up 1966 Ltd is growing −0.2% versus a year earlier (3y avg +6.2%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Novolog Pharm-Up 1966 Ltd (NVLG)?
Earnings per share at Novolog Pharm-Up 1966 Ltd are growing −56.4% versus a year earlier. How much earnings per share grew versus a year earlier.
How much free cash flow does Novolog Pharm-Up 1966 Ltd (NVLG) generate?
The free cash flow of Novolog Pharm-Up 1966 Ltd is −34.2M ILA (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does Novolog Pharm-Up 1966 Ltd (NVLG) carry?
The net debt of Novolog Pharm-Up 1966 Ltd is 61.4M ILA (fiscal year 2025). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed

Watch Novolog Pharm-Up 1966 Ltd in the live analysis

One click puts Novolog Pharm-Up 1966 Ltd on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.